Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • About us
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • Press releases
  • Investors & Media
    • Share information
    • Financial Reports
      • Annual reports
      • Interim reports
      • Year-end reports
    • Presentations
    • Media
      • Image library
      • Video library
    • Analyst Coverage
    • Prospectuses
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • Events
      • Financial calendar
      • General meetings
  • Contact
    • Career
    • Business development
Skip to content

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
AllRegulatory posts
19 January 2023Regulatory Scandion Oncology receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101 Download Presentation Webcast Workbook
18 January 2023Regulatory Scandion Oncology appoints Jan Stenvang, Ph.D., Chief Scientific Officer and member of Executive Management Download Presentation Webcast Workbook
5 December 2022Regulatory Scandion Oncology announces share purchase by incoming President & CEO Download Presentation Webcast Workbook
1 December 2022Regulatory Scandion Oncology appoints Francois Martelet, M.D., as new Chief Executive Officer Download Presentation Webcast Workbook
23 November 2022Regulatory Scandion Oncology announces share purchase by member of the Board of Directors Download Presentation Webcast Workbook
10 November 2022Regulatory Invitation to Scandion Oncology webcast and conference call November 16, 2022 Download Presentation Webcast Workbook
28 October 2022Regulatory Scandion Oncology Announces Results of Extraordinary General Meeting Download Presentation Webcast Workbook
13 October 2022Regulatory Scandion Oncology – Notice convening an Extraordinary General Meeting Download Presentation Webcast Workbook
10 October 2022Regulatory Scandion Oncology initiates part 3 of the CORIST phase II trial Download Presentation Webcast Workbook
30 September 2022Regulatory Scandion Oncology announce topline results from part 2 of the CORIST phase II trial Download Presentation Webcast Workbook
31 August 2022Regulatory Bo Rode Hansen is leaving the position as President and CEO of Scandion Oncology Download Presentation Webcast Workbook
30 August 2022Regulatory Scandion Oncology announce change to its Executive Management Download Presentation Webcast Workbook

Information types

Choose your information types.

Stay updated with news from Scandion Oncology

Subscribe below

Subscription successful. To activate the subscription, we request that you confirm your e-mail address. Do this by clicking on this link in the email we just sent you.
Subscription failed. Error:
  1. Frontpage
  2. Press releases
  3. Press release

About us

  • About us
  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science
  • Patents

Investors & Media

  • Investors & Media
  • Share information
  • Financial Reports
  • Presentations
  • Media
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Contact us

Scandion Oncology A/S
Symbion
Fruebjergvej 3
2100 Copenhagen
Denmark

Phone: +45 38 10 20 17
info@scandiononcology.com

Media and Investor relations:
Email: ir@scandiononcology.com
Phone: +45 29 60 35 32

Follow us


Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Cookie settings | Disclaimer: Market data could be delayed. Delivered by Cision.

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all